The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Feb. 27, 3:44 PM

Slide #22. Seelos Therapeutics, Inc. Secondary Offering

Company: Seelos Therapeutics, Inc. (NASDAQ:SEEL)
Date announced: 2/10/2020
Shares Offered: 6,666,667
Date of Pricing: 2/10/2020
Price Per Share: $0.75
Secondary Offering Details: Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 999,999 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

Seelos Therapeutics is a biopharmaceutical company focused on the development of technologies and therapeutics for the treatment of central nervous system, respiratory and other disorders. Co.'s primary programs are SLS-002, SLS-005 and SLS-006. SLS-002 is intranasal racemic ketamine with two investigational new drug applications, for the treatment of suicidality in post-traumatic stress disorder, and in main depressive disorder. SLS-005, is Trehalose, a protein stabilizer that also activates autophagy and crosses the blood-brain-barrier. Co. is developing Trehalose for the treatment of Sanfilippo syndrome. SLS-006 is a true partial dopamine agonist for Parkinson's disease patients.
Open the SEEL Page at The Online Investor »

Company Name: 
Seelos Therapeutics Inc
Website: 
www.seelostherapeutics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding SEEL: 
3
Total Market Value Held by ETFs: 
$220297
Total Market Capitalization: 
$25.00M
% of Market Cap. Held by ETFs: 
0.88%
 

Open the SEEL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
83rd percentile
(ranked higher than approx. 83% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.